| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $2.39B | -37.1% |
| Cost of Revenue | $809.8M | -23.6% |
| R&D Expense | $196.0M | -39.4% |
| SG&A Expense | $418.5M | -48.8% |
| Operating Income | -$97.4M | -2203.0% |
| Pre-tax Income | -$81.9M | +88.2% |
| Income Tax | $34.8M | +121.9% |
| Net Income | -$104.0M | +80.7% |
| EPS (Basic) | -$1.30 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $960.2M | -46.6% |
| Accounts Receivable | $448.8M | -13.6% |
| Current Assets | $1.54B | -37.8% |
| Total Assets | $7.13B | -25.3% |
| Current Liabilities | $560.9M | -36.7% |
| Long-term Debt | $1.44B | -27.2% |
| Stockholders' Equity | $4.73B | -15.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Capital Expenditures | $19.2M | -70.7% |
| +80.0% |
| EPS (Diluted) | -$1.30 | +80.0% |